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Abstract
Responsibility for the dysfunction of the autonomic nervous system in the 
genesis or aggravation of cardiovascular and/or metabolic disorders is currently 
held. Indeed, a significant correlation between sympathetic overactivity and the 
pathophysiological mechanisms responsible for type 2 diabetes has been proven. 
Therefore, the treatment of this dysautonomia could improve the management of 
type 2 diabetes.
Keywords: the autonomic nervous system, dysautonomia, type 2 diabetes,  
insulino-resistance, insulino-secretion
1. Introduction
The autonomic nervous system (ANS), the dysregulation of which, called 
dysautonomia, is a frequent and often unrecognized condition which is accompa-
nied by polymorphic functional manifestations [1]. The exploration of the ANS 
has gained renewed interest in recent years, due to the demonstration of the major 
role of its alterations in the genesis and aggravation of several diseases [2]. The 
importance of type 2 diabetes (T2DM) comes not only from its growing prevalence 
around the world leading the World Health Organization (WHO) to consider it a 
significantly expanding epidemic; but also given its human and economic conse-
quences, making it a major public health problem.
2. The autonomic nervous system (ANS)
• ANS controls the body’s unconscious, vegetative activities. It ensures the normal 
functioning of vegetative functions (breathing, heart rate, blood pressure, 
digestion, secretions, body temperature, water balance, etc.), and responds 
instantly to all physical and emotional demands. It is a system of adaptation of 
the body to its environment [2].
• The autonomic nervous system consists of two functionally and, in large part, 
morphologically distinct parts [3]:
 ○ The orthosympathetic (or sympathetic) system which intervenes in the 
involuntary activities of the stressful and arousal situations. It is preponderant 
in the conflicts of the organism with its external environment, when life is 
threatened. The sympathetic system stimulates all the organs that play a role in 
the defense response. The sympathetic nerve centers are essentially bulbospinal 
and their organization is segmental. The preganglionic fibers exit through the 
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ventral root of the corresponding spinal nerve. They separate to form the white 
communicating branch which joins the corresponding para-vertebral ganglion. 
These paravertebral ganglia are united in a chain by inter-ganglionic fibers. The 
fibers which exit from the paravertebral ganglia join the corresponding spinal 
nerve by the gray communicating branch to go to the target organ.
 ○ The parasympathetic system which takes care of the involuntary activities 
of the situations of relaxation and rest. Its nerve centers are located in the 
brainstem and the sacral marrow. The preganglionic fibers follow the path of 
the corresponding nerves. They synapse into a pre-visceral or intra-visceral 
ganglion. The parasympathetic system therefore does not have a structure 
equivalent to the chain of sympathetic paravertebral ganglia.
• The autonomic or vegetative nervous system is made up of several levels:
a. Nervous centers located within the central nervous system (medulla 
oblongata, thalamus and hypothalamus.) and in the spinal cord, constitute 
the “motor” of the autonomic nervous system.
b. Peripheral ganglia located on three floors:
 ○ The first ganglionic stage comprises the para- vertebral sympathetic 
chain. This chain is located laterally in the spine and extends from 
the end of the cervical segment to the coccygeal segment. It includes 
3 cervical ganglia, superior, middle and inferior through which the 
sympathetic fibers of the cervical segment pass.
 ○ A second ganglionic stage consists of the pre-visceral ganglia or 
plexus. They are less numerous than the paravertebral ganglia. They 
are more ganglion plexuses than ganglia. They are paired and lateral 
in the neck (carotid plexus, pharyngeal, …) and pelvis but single 
and medial in the thorax (cardiac, pulmonary plexus) and abdomen 
(solar plexus, lumbo-aortic). At the cervical level, this second stage is 
associated with the 1st stage.
 ○ A third lymph node stage includes the visceral or terminal lymph 
nodes located on the surface or in the thickness of the target organ.
c. Fibers that connect these levels to each other and to the viscera:
Between the nerve center and the target organ, the autonomic nervous 
path is always interrupted by at least one synapse located in a ganglion.
An autonomous nerve pathway is therefore made up of at least two fibers: 
the pre-ganglionic fiber and the post-ganglionic fiber.
The nerve fibers of the autonomic system travel either alongside the fibers 
of the somatic system (mixed nerves) or independently, along the blood 
vessels. Norepinephrine is the neurotransmitter at all levels of the sympa-
thetic system, except the ganglionic (acetylcholine) level, while acetylcholine 
mediates the parasympathetic or vagal system.
• There is a strong interaction between the autonomic nervous system and the 
endocrine system, especially the hypothalamic–pituitary–adrenal axis. Also, 
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sympathetic hyperactivity is implicated in various symptoms or pathologies 
such as essential hypertension [4], obesity [4, 5], permanent resting tachycardia, 
hyperlipidemia, type 2 diabetes [5], sleep apnea [5] or sedentary lifestyle.
3. The ANS measurement methods
• Considered difficult, the assessment of ANS activity has been greatly facili-
tated by the development of systems allowing non-invasive clinical exploration 
based mainly on the continuous recording of blood pressure and heart rate by a 
Holter ECG [6].
• Sympathetic activity can be measured directly by the technique of micro-
neurography which measures muscle sympathetic nerve activity (ANSM) by 
inserting electrodes into a nerve (usually the peroneal nerve). This technique is 
very precise and minimally invasive.
• On the other hand, the measurement of the “spill over” of catecholamines is 
reliable but is not easily applicable due to its very invasive nature. We can also 
measure catecholamines and their metabolites (metanephrines) in peripheral 
blood or 24 hours urine, but studies show that plasma catecholamine levels are 
not sensitive markers of sympathetic activity. Also, they objectify that the urinary 
catecholamines are not sufficiently sensitive to estimate the sympathetic [6].
4. Epidemiological data
• The importance of the type 2 diabetes (T2DM) stems from:
 ○ Its increasing prevalence throughout the world, around 463 million diabetics 
in 2019 according to IDF, and to increase to 700 million in 2045.
 ○ Its association with a remarkable increase in cardiovascular morbidity and 
mortality.
• The 2000 World Diabetes Congress in Mexico City placed particular emphasis 
on the metabolic syndrome by sounding the alarm on the impact of such a 
prevalence on the population. This puts the metabolic syndrome and diabetes 
far ahead of HIV-AIDS in terms of morbidity and mortality.
5. Relationship between type 2 diabetes and ANS
A global approach of the responsibility of a dysfunction of the ANS in the 
genesis or the aggravation of the 3 main pathophysiological mechanisms of type 2 
diabetes, which are insulin resistance, decrease in insulin secretion and hypergluca-
gonemia, has been attempted, by several studies all over the world especially during 
the last decades.
a. ANS and insulinoresistance
• Currently there is evidence that sympathetic hyperactivity is responsible for 
resistance to the action of insulin. Indeed, it can even precede the installation 
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of this insulin resistance [7]. Activation of adrenergic receptors, in particu-
lar β-adrenergic receptors, has been shown to transform the phenotype of 
muscle cells into insulin-resistant cells [8].
• Variation of adrenaline and noradrenaline may also reduce insulin-induced 
glucose uptake. The aforementioned metabolic abnormalities are associated 
with a depletion of capillaries which reduces the supply of nutrients to the 
muscles which are therefore largely involved in insulin resistance [9, 10].
• In a recent longitudinal study, Flaa A. et al. studied the relationship between 
sympathetic activity and future insulin resistance in healthy Caucasian 
subjects with 18 years of follow-up [11]. They found that sympathetic activity 
was a predictor of insulin resistance as measured by HOMA-IR (Homeostasis 
model assessement- Insulin resistance: is a method for assessing β-cell func-
tion and insulin resistance (IR) from basal (fasting) glucose and insulin or 
C-peptide concentrations).
• In addition, there is a strong inflammatory activity in abdominal obesity with 
macrophage infiltration of visceral adipose tissue. These macrophages will 
be responsible for the secretion of pro-inflammatory factors such as interleu-
kin 6 (IL6) or tumor necrosis factor alpha (TNF alpha) [12]. The secretion 
of these two cytokines by the visceral adipose tissue in obesity may play a 
specific role in the development of insulin resistance. Indeed, these factors 
can activate inhibitory pathways of the insulin cascade which will therefore 
have less effect on sensitive peripheral tissues (skeletal muscle and liver for 
example) and therefore induce insulin resistance [13].
Figure 1. 
Schematic representation of the association between sympathic hyperactivity and the different metabolic and 
cardiovascular pathologies [8]. Sympathetic overactivity is implicated in various symptoms or pathologies such 
as essential hypertension, obesity, permanent resting tachycardia, hyperlipidemia, type 2 diabetes, sleep apnea.
5
Type 2 Diabetes and Dysautonomy
DOI: http://dx.doi.org/10.5772/intechopen.95043
• These results provide new information on the pathophysiological mechanisms 
of insulin resistance, suggesting that sympathetic overactivity may be a predis-
posing factor for future insulin resistance (Figure 1).
b. ANS and insulinosecretion:
There are hormones that are part of the metabolic extension of the sympa-
thetic while others are the metabolic extension of the parasympathetic. Insulin 
is part of the parasympathetic-vagal tendency.
The vagal deficiency secondary to T2DM is added to the depletion of the beta 
cells of the islets of Langerhans in the pancreas, thus exacerbating the insulin 
deficiency of type 2 diabetics [14].
c. ANS and hyperglucagonemia:
There is a microcirculation within the islets of Langerhans. Arterial blood first 
passes through “β” cells and “δ” cells (somatostatin) before reaching “α” cells 
which therefore do not respond directly to hyperglycemia. Hyperglucagonemia 
is secondary on the one hand to a direct stimulatory sympathetic action on “α” 
cells; and on the other hand, to a vagal deficiency responsible for the lifting of 
the inhibition on the “α” cells and a decrease in the stimulation of the “β” cells 
responsible for a decrease in GABA and molecules contained in the granules 
(Zinc) [15].
6. Outlook
To date, little therapeutic benefit has been gained from this information, since 
centrally acting sympatho-inhibitory drugs and alpha and beta blockers are used in 
the treatment of arterial hypertension.
Beta blockers are known to make diabetes worse. On the other hand, quite inter-
estingly, drugs having a central sympatho-inhibitory action, such as clonidine and 
rilmenidine, are neutral or even slightly beneficial in diabetes and the metabolic 
syndrome.
Antidepressants, especially selective serotonin reuptake inhibitors (SSRIs) 
can be extremely effective in regulating the autonomic nervous system and blood 
pressure. At the same time, some studies indicate that serotonin-norepinephrine 
reuptake inhibitors (a SNRI) are even more effective.
These data may also lead to the proposal of sympathetically inhibiting drugs of 
central action in patients with metabolic syndrome in order to reduce the cardiovas-
cular and metabolic consequences and perhaps even better in the unincorporated 
phases of the MS hoping to reduce the probability of evolution towards the consti-
tuted SM.
7. Conclusion
The responsibility of sympathetic dysfunction in the genesis or aggravation of 
cardiovascular and/or metabolic disorders is currently confirmed.
The consequences could vary depending on the genotypic and phenotypic 
characteristics of individuals and their environment, this encourages us to always 
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explore the autonomic nervous system as part of the etiological assessment of the 
metabolic syndrome in general or of arterial hypertension and T2DM in particular.
The metabolic and functional consequences of ANS dysfunction could have a 
role not only in the genesis of T2DM but also in the development of complications 
and in its management.
A predominance of the sympathetic over the parasympathetic is responsible for 
insulin resistance, impaired insulin secretion and hyperglucagonemia, hence the 
importance of the exploration of the S.N.A both for screening and for management.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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